RORC and hematologic disorder: Thus, these preclinical findings suggest that an mTORC1-selective bi-steric inhibitor has the potential to provide an improved therapeutic window over TOR-KIs by achieving durable mTORC1 inhibition while minimizing inhibition of mTORC2 and related kinases, as well as provide the practical benefits of an intermittent dosing regimen, in hematologic malignancies.